Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for cancer treatment. ADCs are complex molecules composed of an antibody linked - via a stable, chemical linker with labile bonds - to a biological active cytotoxic (anticancer) payload or drug.


By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, ADCs enable sensitive discrimination between healthy and diseased tissue, so that healthy cells are less severely affected. This targeted approach stands in contrast to traditional chemotherapeutic agents, offering a more focused and effective cancer treatment strategy.


MedKoo provides a wide range of services to support the characterization and development of various antibody forms applicable to ADCs, including most of the monoclonal and engineered antibodies on our website. Our scientists are pleased to offer site-specific antibody-drug conjugation services, utilizing both traditional and unique conjugation strategies developed at Medkoo. Small drugs or toxins can be conjugated to an antibody at a specific site away from the antigen binding site.


Our antibody-drug conjugation services include: